- Drug Pipelines
- December 2022
- 30 Pages
Global
From €2860EUR$3,250USD£2,490GBP
- Drug Pipelines
- December 2022
- 30 Pages
Global
From €2420EUR$2,750USD£2,107GBP
- Drug Pipelines
- December 2022
- 30 Pages
Global
From €2420EUR$2,750USD£2,107GBP
- Report
- September 2022
- 30 Pages
Global
From €2420EUR$2,750USD£2,107GBP
- Report
- September 2022
- 30 Pages
Global
From €2860EUR$3,250USD£2,490GBP
- Report
- September 2022
- 70 Pages
Global
From €3476EUR$3,950USD£3,027GBP
- Report
- September 2022
- 135 Pages
Global
From €6600EUR$7,500USD£5,747GBP
- Report
- August 2022
- 181 Pages
Global
From €6600EUR$7,500USD£5,747GBP
- Report
- August 2022
- 77 Pages
Global
From €3476EUR$3,950USD£3,027GBP
- Report
- August 2022
- 218 Pages
Global
From €6600EUR$7,500USD£5,747GBP
- Report
- August 2022
- 109 Pages
Global
From €3476EUR$3,950USD£3,027GBP
- Report
- January 2022
- 60 Pages
Global
From €3476EUR$3,950USD£3,027GBP
- Report
- January 2022
- 60 Pages
Global
From €3476EUR$3,950USD£3,027GBP
- Report
- August 2020
- 80 Pages
Global
From €2420EUR$2,750USD£2,107GBP
- Report
- August 2020
- 80 Pages
Global
From €2420EUR$2,750USD£2,107GBP
- Report
- February 2020
- 120 Pages
Global
From €3960EUR$4,500USD£3,448GBP
- Report
- March 2024
- 200 Pages
Global
From €3652EUR$4,150USD£3,180GBP
- Report
- July 2023
- 145 Pages
Global
From €2772EUR$3,150USD£2,414GBP
- Report
- April 2023
- 110 Pages
Global
From €4180EUR$4,750USD£3,639GBP
- Report
- June 2025
- 250 Pages
India
From €2454EUR$2,789USD£2,137GBP

The Respiratory Drugs market is a sector of the pharmaceutical industry that focuses on the development and production of drugs used to treat respiratory diseases. These drugs are used to treat a variety of conditions, including asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis. Commonly prescribed respiratory drugs include bronchodilators, corticosteroids, and antibiotics.
The Respiratory Drugs market is highly competitive, with many large pharmaceutical companies vying for market share. Companies in the market include GlaxoSmithKline, AstraZeneca, Merck & Co., Novartis, and Boehringer Ingelheim. These companies are constantly researching and developing new drugs to treat respiratory diseases, as well as improving existing treatments. Show Less Read more